EP4153167A4 - Verfahren zur behandlung von aml-subtypen mit arginin-depletionsmitteln - Google Patents

Verfahren zur behandlung von aml-subtypen mit arginin-depletionsmitteln Download PDF

Info

Publication number
EP4153167A4
EP4153167A4 EP20943510.6A EP20943510A EP4153167A4 EP 4153167 A4 EP4153167 A4 EP 4153167A4 EP 20943510 A EP20943510 A EP 20943510A EP 4153167 A4 EP4153167 A4 EP 4153167A4
Authority
EP
European Patent Office
Prior art keywords
treating aml
arginine depletion
aml subtypes
depletion agents
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20943510.6A
Other languages
English (en)
French (fr)
Other versions
EP4153167A1 (de
Inventor
Sui Yi Kwok
Norman Fung Man Wai
Terence Shau Yin WAI
Yun Chung Leung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vision Global Holdings Ltd
Original Assignee
Vision Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vision Global Holdings Ltd filed Critical Vision Global Holdings Ltd
Publication of EP4153167A1 publication Critical patent/EP4153167A1/de
Publication of EP4153167A4 publication Critical patent/EP4153167A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20943510.6A 2020-06-29 2020-06-29 Verfahren zur behandlung von aml-subtypen mit arginin-depletionsmitteln Withdrawn EP4153167A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/098681 WO2022000151A1 (en) 2020-06-29 2020-06-29 Method of treating aml subtypes using arginine-depleting agents

Publications (2)

Publication Number Publication Date
EP4153167A1 EP4153167A1 (de) 2023-03-29
EP4153167A4 true EP4153167A4 (de) 2024-02-28

Family

ID=79317763

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20943510.6A Withdrawn EP4153167A4 (de) 2020-06-29 2020-06-29 Verfahren zur behandlung von aml-subtypen mit arginin-depletionsmitteln

Country Status (6)

Country Link
EP (1) EP4153167A4 (de)
KR (1) KR20230104110A (de)
CN (1) CN115697320A (de)
CA (1) CA3187578A1 (de)
TW (1) TW202206095A (de)
WO (1) WO2022000151A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115038460A (zh) * 2019-12-02 2022-09-09 香港理工大学 诱导间歇性禁食和调节自噬的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015512A1 (en) * 2004-08-11 2006-02-16 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. A modified arginine deiminase
WO2013151568A1 (en) * 2012-04-04 2013-10-10 Polaris Group Methods of treatment with arginine deiminase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255262B2 (en) * 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
TWI847958B (zh) * 2016-07-05 2024-07-11 英屬開曼群島商北極星藥業集團股份有限公司 用精胺酸耗盡劑進行之組合癌症免疫療法
CN110191721A (zh) * 2016-09-26 2019-08-30 集合集团控股公司 有淋巴系统失调的受试者中癌症的评估与治疗方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015512A1 (en) * 2004-08-11 2006-02-16 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. A modified arginine deiminase
WO2013151568A1 (en) * 2012-04-04 2013-10-10 Polaris Group Methods of treatment with arginine deiminase

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHOW JEREMY P. H. ET AL: "A modified arginine-depleting enzyme NEI-01 inhibits growth of pancreatic cancer cells", PLOS ONE, vol. 15, no. 4, 30 April 2020 (2020-04-30), US, pages e0231633, XP093119859, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0231633 *
DATABASE Geneseq [online] 15 June 2007 (2007-06-15), "Arginine deiminase.", retrieved from EBI accession no. GSP:AEF74467 Database accession no. AEF74467 *
DATTA SAYANTAP ET AL: "Human Arginase I (Arg I)-A Potential Broad-spectrum Anti-cancer Agent: Perspectives and the Road Ahead", RESEARCH & REVIEWS: JOURNAL OF ONCOLOGY AND HEMATOLOGY, vol. 9, no. 3, 1 January 2020 (2020-01-01), pages 23 - 35, XP055972770, DOI: 10.37591/rrjooh.v9i3.2312 *
See also references of WO2022000151A1 *
TSAI HUI-JEN ET AL: "A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients", SCIENTIFIC REPORTS, vol. 7, no. 1, 12 September 2017 (2017-09-12), US, pages 1 - 10, XP055886883, ISSN: 2045-2322, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-017-10542-4.pdf> DOI: 10.1038/s41598-017-10542-4 *

Also Published As

Publication number Publication date
WO2022000151A1 (en) 2022-01-06
EP4153167A1 (de) 2023-03-29
CN115697320A (zh) 2023-02-03
TW202206095A (zh) 2022-02-16
CA3187578A1 (en) 2022-01-06
KR20230104110A (ko) 2023-07-07

Similar Documents

Publication Publication Date Title
EP3976195A4 (de) Verfahren zur behandlung von kleinzelligen neuroendokrinem karzinom und assoziierten karzinomen
EP4054588A4 (de) Verfahren zur behandlung mit myosin-modulator
EP4157324A4 (de) Pth-analoga zur behandlung von hypoparathyreose
EP4132507A4 (de) Verfahren zur behandlung von coronavirusinduzierten entzündungszuständen
EP4143204A4 (de) Verfahren zur behandlung von covid-19
EP4380566A4 (de) Verfahren zur behandlung von migräne mit mnk-hemmern
EP4100019A4 (de) Verfahren zur behandlung von coronavirus-infektionen
EP4441206A4 (de) Verfahren zur behandlung von akuter myeloischer leukämie
EP4181925A4 (de) Verfahren zur behandlung von proteinopathien
EP4262841A4 (de) Verfahren zur behandlung von fibrose
EP4365362A4 (de) Vorrichtung zur behandlung von kleidungsstücken
EP4087564A4 (de) Verfahren zur behandlung von umherirren im zusammenhang mit kortikaler demenz
EP4310238A4 (de) Vorrichtung zur behandlung von kleidungsstücken
EP4538446A4 (de) Vorrichtung zur behandlung von kleidungsstücken
EP3914589A4 (de) Verfahren zur behandlung von krankheiten mit magl-hemmern
EP4225371A4 (de) Verfahren zur behandlung von ox40-verwandten krankheiten
EP4153167A4 (de) Verfahren zur behandlung von aml-subtypen mit arginin-depletionsmitteln
EP4034109A4 (de) Verfahren und zusammensetzung zur behandlung von erkrankungen
EP4376885A4 (de) Verfahren zur behandlung von akuter myeloischer leukämie mit anti-ilt3-antikörpern
EP3713882C0 (de) Verfahren zur behandlung von abwasser
EP3742899C0 (de) Verfahren zur behandlung von citrus-greening
EP4365357A4 (de) Vorrichtung zur behandlung von kleidungsstücken
EP4036301C0 (de) Vorrichtung zur behandlung von wäsche
EP4132503A4 (de) Verfahren zur behandlung von coronavirus-infektionen
EP4063506A4 (de) Verfahren zur vorbeugung oder behandlung von cholesterinbedingten krankheiten unter verwendung eines anti-pcsk9-antikörpers

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082514

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240129

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/765 20060101ALI20240123BHEP

Ipc: C07K 14/00 20060101ALI20240123BHEP

Ipc: A61K 31/335 20060101AFI20240123BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240817